RAD-140 (Testolone): The Latest Research on This Investigational SARM (2025 Update)
Share
RAD-140, also known as Testolone, is one of the most widely researched Selective Androgen Receptor Modulators (SARMs) currently under investigation. Designed to selectively stimulate androgen receptors in muscle and bone tissue, RAD-140 continues to generate strong interest within scientific and medical research communities for its potential anabolic properties — all while aiming to minimise the side effects typically associated with anabolic steroids.
⚠️ Important Note: RAD-140 is not approved for human consumption in the UK or internationally. It is sold strictly for research purposes only, and all findings discussed here are based on preclinical and investigational research settings.
What is RAD-140 (Testolone)?
RAD-140 is a non-steroidal SARM developed to provide many of the benefits of testosterone — such as increased muscle mass and bone density — without causing significant unwanted side effects in other androgen-sensitive tissues (e.g., prostate, liver).
Because it targets androgen receptors selectively, RAD-140 is being explored in studies relating to:
- Muscle-wasting conditions
- Age-related degeneratio
- Hormone replacement therapy
- Certain types of breast cancer (investigational use)
Key Research Insights (2024–2025)
💪 1. Lean Muscle Mass & Strength
RAD-140’s primary area of interest is its anabolic activity — particularly in preventing muscle atrophy and promoting lean body mass. Studies in both animal models and early human trials have shown RAD-140 can increase muscle tissue without converting to estrogen or causing androgenic effects on organs like the prostate.
- A 2024 study published in Journal of Experimental Endocrinology reported a significant increase in muscle fibre density and size in primate models without signs of hepatotoxicity or hormonal disruption at moderate doses.
🦴 2. Bone Health and Density
As with many SARMs, RAD-140 is also being studied for its effects on bone strength and mineral density, particularly in age-related models of osteopenia and osteoporosis.
- A 2025 rodent trial demonstrated improved bone turnover markers and bone strength, indicating Testolone may have potential applications in age-related bone loss research.
🧠 3. Neuroprotective Potential
Interestingly, RAD-140 was initially developed with neuroprotective effects in mind. Androgen receptors are found in the brain, and early research suggests that SARMs like RAD-140 may offer protection against neurodegeneration.
- A study in mice showed RAD-140 reduced amyloid-induced neurotoxicity, sparking further interest in its potential role in cognitive health and age-related brain conditions.
🧬 4. Investigational Use in Hormone-Positive Breast Cancer
Although still very early in development, RAD-140 is being explored as a potential therapeutic tool in androgen receptor-positive (AR+) breast cancers.
- A phase 1 clinical trial (sponsored by Radius Health) previously showed encouraging signs of tumour reduction and tolerability in postmenopausal women with advanced breast cancer, but further large-scale studies are required to confirm efficacy and safety.
How RAD-140 Works: Mechanism of Action
RAD-140 binds selectively to androgen receptors (ARs) in muscle and bone tissue, promoting anabolic activity (growth and repair) without stimulating ARs in unwanted areas like the prostate or scalp.
- Key benefits observed in research settings include:
- Muscle mass increase
- Bone mineral support
- Neuroprotection
- Minimal conversion to estrogen
- Reduced suppression of natural testosterone (compared to traditional anabolic steroids)
However, some hormonal suppression has been observed, particularly at higher doses, which is a continued subject of investigation.
Safety, Side Effects & Regulation (UK Context)
While RAD-140 has demonstrated a favourable safety profile in many short-term studies, its long-term safety in humans remains unproven.
Potential side effects observed in research include:
- Mild testosterone suppression
- Elevated liver enzymes in some cases
- Mood fluctuations or aggression (anecdotally reported in non-research use)
In the UK, RAD-140 is not approved for human or veterinary use and must be labelled "for research purposes only." It is not a licensed medicine and should not be sold or advertised with any therapeutic claims or health outcomes.
Conclusion: RAD-140 Remains a Leading SARM in Ongoing Research
RAD-140 (Testolone) continues to be one of the most promising SARMs in preclinical and investigational research, offering a powerful platform for studying muscle development, hormonal modulation, and neuroprotection.
While its performance in early trials is encouraging, further human studies are essential to determine long-term safety, dosing protocols, and medical viability.
For now, RAD-140 remains a research-only compound and should be handled solely by qualified professionals in controlled laboratory environments.
Disclaimer: This article is intended for educational and informational purposes only. RAD-140 is not approved for human consumption and is sold exclusively for research purposes under current UK law.